|
|
 |
|
Viewing report
|
|
|
|
Access to Hospital Pharmaceutical Markets in the United Kingdom
Just Pharma Reports, Aug 2008, Pages: 81
Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of specialty products emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they remain poorly documented and often little understood.
This report aims to clarify the situation for the UK, a particularly challenging country with four different public healthcare systems, numerous stakeholders, regular reforms, and rigorous health technology assessment. Medicines prescribed in English hospitals alone in 2006 were valued at £2.7 billion (€3.4 billion/$5.4 billion). This represented 24% of the English NHS drugs bill (but hospital prescribing in London accounted for 40% of all prescribing costs). Even more significantly, the hospital drug bill has been rising at more than twice the rate of GP prescribing costs.
This report provides:
- Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for.
- Separate sections on England, Scotland, Wales and Northern Ireland.
- Full coverage of the NHS plus two of the largest private providers.
- Explanation of tendering, contracting, contract adjudication and other aspects of procurement.
- Clarification of the DRG type funding system, Payment by Results.
- Special focus on oncology.
- What discounts hospitals expect and why value added tax is a concern.
- Features on risk sharing schemes and on the boom in homecare services.
- NICE, the PPRS and much, much more…
Customers who bought this item also bought
Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pharmaceutical Cost Containment in Europe: National Governments Tighten the Screws
Special Report: The Pricing and Reimbursement Environment for Autoimmune Biologics
Pricing and Reimbursement of Targeted Cancer Therapies
Pharmaceutical Industry Market Review 2008
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
New Approaches to Gaining Market Access for Pharmaceuticals: Pricing & Reimbursement, Policy Development, and the Role of HTAs
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
|
|
|
|
